![]() Until recently, the only treatment with the possibility of eliminating recurrent or treatment-resistant diffuse large B-cell lymphoma was more high-dose chemotherapy, followed by an autologous stem cell transplant. And for future studies, axi-cel “is now the benchmark upon which to improve with future treatments,” Dr. Jason Westin, M.D., of the University of Texas MD Anderson Cancer Center, who helped lead the study.Īnd with patients being followed for almost 4 years, those still alive have likely been cured, he added.īased on these results, axi-cel is now the preferred treatment for people whose diffuse large B-cell lymphoma has recurred quickly or proven resistant to standard initial treatment, explained Christopher Melani, M.D., of NCI’s Center for Cancer Research. “This is the first trial in nearly 30 years to significantly improve overall survival for patients with large B-cell lymphoma that is not responding to initial treatment or has relapsed,” said Dr. They estimate that about 55% of patients would still be alive 4 years after receiving axi-cel, compared with 46% of those who initially received the standard treatment for relapsed disease. ![]() The study investigators presented their findings June 5 at the American Society of Clinical Oncology (ASCO) annual meeting. Now, new data from the ZUMA-7 clinical trial strongly suggests that axi-cel, as this CAR T-cell therapy is often called, can offer real hope for this latter group of patients. But for those who aren’t, the prospects of a cure have been uncertain at best, even with additional grueling chemotherapy and stem cell transplant. Most people diagnosed with diffuse large B-cell lymphoma, the most common form of aggressive NHL, will be cured by initial treatment with chemotherapy. That’s according to updated results from a large randomized phase 3 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (Yescarta). ![]() CAR T-cell therapy, a type of personalized immunotherapy, can help cure some people with aggressive non-Hodgkin lymphoma (NHL).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |